NTY logo

Nabriva Therapeutics BST:NTY Stock Report

Last Price

€1.39

Market Cap

€4.6m

7D

0%

1Y

-82.2%

Updated

30 Apr, 2023

Data

Company Financials

NTY Stock Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.

NTY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Nabriva Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nabriva Therapeutics
Historical stock prices
Current Share PriceUS$1.39
52 Week HighUS$8.50
52 Week LowUS$0.26
Beta1.55
1 Month Change0%
3 Month Changen/a
1 Year Change-82.18%
3 Year Change-98.92%
5 Year Change-99.86%
Change since IPO-99.92%

Recent News & Updates

Recent updates

Shareholder Returns

NTYDE PharmaceuticalsDE Market
7D0%3.0%1.3%
1Y-82.2%-25.6%6.4%

Return vs Industry: NTY underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.

Return vs Market: NTY underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is NTY's price volatile compared to industry and market?
NTY volatility
NTY Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: NTY has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NTY's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200539J. Naftzgerhttps://www.nabriva.com

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections.

Nabriva Therapeutics plc Fundamentals Summary

How do Nabriva Therapeutics's earnings and revenue compare to its market cap?
NTY fundamental statistics
Market cap€4.65m
Earnings (TTM)-€51.90m
Revenue (TTM)€33.52m

0.1x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NTY income statement (TTM)
RevenueUS$36.94m
Cost of RevenueUS$47.16m
Gross Profit-US$10.23m
Other ExpensesUS$46.96m
Earnings-US$57.18m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-17.86
Gross Margin-27.69%
Net Profit Margin-154.83%
Debt/Equity Ratio158.5%

How did NTY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.